AstraZeneca shares drop as lung cancer trial update lags expectations
By Maggie Fick and Ludwig Burger (Reuters) – AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company’s shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped. The drug, datopotamab deruxtecan, which is being jointly developed…
